Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.

Twu CW, Wang WY, Chen CC, Liang KL, Jiang RS, Wu CT, Shih YT, Lin PJ, Liu YC, Lin JC.

Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):21-9. doi: 10.1016/j.ijrobp.2014.01.052.

PMID:
24725686
2.

Long-term clinical outcome in nasopharyngeal carcinoma patients with post-radiation persistently detectable plasma EBV DNA.

Wang WY, Lin TY, Twu CW, Tsou HH, Lin PJ, Liu YC, Huang JW, Hsieh HY, Lin JC.

Oncotarget. 2016 Jul 5;7(27):42608-42616. doi: 10.18632/oncotarget.9323.

3.

Can plasma Epstein-Barr virus DNA levels be used to monitor nasopharyngeal carcinoma progression?

Farrell PJ.

Nat Clin Pract Oncol. 2005 Jan;2(1):14-5. No abstract available.

PMID:
16264847
4.
5.

Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma.

Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, Jiang RS.

N Engl J Med. 2004 Jun 10;350(24):2461-70.

7.

Failure patterns and survival in patients with nasopharyngeal carcinoma treated with intensity modulated radiation in Northwest China: a pilot study.

Wang J, Shi M, Hsia Y, Luo S, Zhao L, Xu M, Xiao F, Fu X, Li J, Zhou B, Long X.

Radiat Oncol. 2012 Jan 10;7:2. doi: 10.1186/1748-717X-7-2.

8.

Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels.

Wang WY, Twu CW, Chen HH, Jiang RS, Wu CT, Liang KL, Shih YT, Chen CC, Lin PJ, Liu YC, Lin JC.

Cancer. 2013 Mar 1;119(5):963-70. doi: 10.1002/cncr.27853. Epub 2012 Oct 12.

9.

Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA.

Chan AT, Ma BB, Lo YM, Leung SF, Kwan WH, Hui EP, Mok TS, Kam M, Chan LS, Chiu SK, Yu KH, Cheung KY, Lai K, Lai M, Mo F, Yeo W, King A, Johnson PJ, Teo PM, Zee B.

J Clin Oncol. 2004 Aug 1;22(15):3053-60.

PMID:
15284255
10.
11.

A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients.

Chi KH, Chang YC, Guo WY, Leung MJ, Shiau CY, Chen SY, Wang LW, Lai YL, Hsu MM, Lian SL, Chang CH, Liu TW, Chin YH, Yen SH, Perng CH, Chen KY.

Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1238-44.

PMID:
11955734
12.

Enhancement of local control in locally advanced node-positive nasopharyngeal carcinoma by adjunctive chemotherapy.

Teo PM, Chan AT, Lee WY, Leung TW, Johnson PJ.

Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):261-71.

PMID:
10030248
14.

Treatment of Stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation: impact of chemotherapy schemes.

Yau TK, Lee AW, Wong DH, Pang ES, Ng WT, Yeung RM, Soong IS.

Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1004-10.

PMID:
17145529
15.

The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.

Liu LT, Tang LQ, Chen QY, Zhang L, Guo SS, Guo L, Mo HY, Zhao C, Guo X, Cao KJ, Qian CN, Zeng MS, Bei JX, Hong MH, Shao JY, Sun Y, Ma J, Mai HQ.

Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):862-9. doi: 10.1016/j.ijrobp.2015.08.003. Epub 2015 Aug 7.

PMID:
26530755
16.

[Prognostic impact of plasma Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma].

Hou X, Zhang L, Zhao C, Li S, Lu LX, Han F, Shao JY, Huang PY.

Ai Zheng. 2006 Jul;25(7):785-92. Chinese.

PMID:
16831265
17.

Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma.

Hui EP, Ma BB, Chan KC, Chan CM, Wong CS, To KF, Chan AW, Tung SY, Ng WT, Cheng AC, Lee VH, Chan SL, Loong HH, Kam MK, Leung SF, Ho R, Mo F, Ngan RK, Chan AT.

Cancer. 2015 Aug 15;121(16):2720-9. doi: 10.1002/cncr.29413. Epub 2015 May 6.

18.

Concomitant chemoirradiation for stage III-IV nasopharyngeal carcinoma in Chinese patients: results of a matched cohort analysis.

Chua DT, Sham JS, Au GK, Choy D.

Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):334-43.

PMID:
12023137
19.

Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma: results of a matched cohort study.

Geara FB, Glisson BS, Sanguineti G, Tucker SL, Garden AS, Ang KK, Lippman SM, Clayman GL, Goepfert H, Peters LJ, Hong WK.

Cancer. 1997 Apr 1;79(7):1279-86.

PMID:
9083147
20.

Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china.

Chen Y, Liu MZ, Liang SB, Zong JF, Mao YP, Tang LL, Guo Y, Lin AH, Zeng XF, Ma J.

Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1356-64. doi: 10.1016/j.ijrobp.2007.12.028. Epub 2008 May 9.

PMID:
18472356

Supplemental Content

Support Center